Key result
Captopril, but not diltiazem, significantly reduced proteinuria (149 vs 616 mg/day, p<0.01) and serum creatinine (0.36 vs 0.58 mg%, p<0.01) compared to untreated rats with adriamycin nephropathy.
Why the study?
Does captopril or diltiazem improve renal outcomes in rats with early adriamycin nephropathy?
Population
Rats with early adriamycin (ADR) nephropathy
Comparison
Captopril or Diltiazem vs Untreated ADR rats
Design
Preclinical
Follow-up
20 weeks
Authors
Loading...
May support ACEI preference in this rat model; leaves open translation to human proteinuric kidney disease.
Does captopril or diltiazem improve renal outcomes in rats with early adriamycin nephropathy?
Absolute Event Rate: 149% vs 616%
p-value: p=<0.01
Captopril, but not diltiazem, prevents the progression of early glomerular injury and renal insufficiency in a rat model of adriamycin nephropathy.
Podjarny et al. (2008) studied Adriamycin (ADR) nephropathy / early chronic renal disease. Captopril (CEI) and Diltiazem (CCB) vs. Untreated ADR rats was evaluated on Proteinuria (mg/day) (p=<0.01). Captopril, but not diltiazem, significantly reduced proteinuria (149 vs 616 mg/day, p<0.01) and serum creatinine (0.36 vs 0.58 mg%, p<0.01) compared to untreated rats with adriamycin nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: